Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTRACT: Biomarker Directed Therapy vs Clinician's Choice in mCRPC Post Abiraterone
NCT04015622Phase 2Active, not recruiting
- Sponsor
- BC Cancer
- Start
- Oct 2020
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enzalutamide, docetaxel in metastatic castration-resistant prostate cancer (mCRPC), sponsored by BC Cancer. Started Oct 2020; status: active, not recruiting.
02
Drugs
enzalutamidedocetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT04015622.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04015622.